Health Economics›Bladder cancer›Neoadjuvant chemotherapy

Neoadjuvant chemotherapy

Bladder cancer · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~4.7 mo	~11.5 mo	~11	~R 3 156 508 PFS proxy · indirect	4
Cisplatin and Gemcitabine (GC) and Pembrolizumab Variant #01	—	R 85 180	21d	~8.3 mo	~17.0 mo	~13	~R 1 107 338 PFS proxy · indirect	2
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	~24.3 mo	—	—	3
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	—	—	—	—	1
MVAC, dose-dense Variant #01	—	R 3 841	14d	—	—	—	—	1
MVAC Variant #01	—	R 1 082	28d	—	89.5 mo	—	—	1
MCV Variant #01	—	R 795	28d	—	44.0 mo	—	—	1
No neoadjuvant therapy Partial	—	—	—	—	46.0 mo	—	—	2

8 of 8 regimens shown